MYNZ Intrinsic Stock Value – MAINZ BIOMED NV Reports Q2 FY2023 Earnings Results
August 25, 2023
🌥️Earnings Overview
MAINZ BIOMED NV ($NASDAQ:MYNZ) reported their financial results for the second quarter of FY2023, ending on June 30 2023. Total revenue for this period was USD 0.2 million, up 78.6% from the same quarter of the previous year. Net income for Q2 2023 was USD -8.2 million, an improvement from the previous year’s figure of -6.9 million.
Share Price
MAINZ BIOMED NV reported its Q2 FY2023 earnings results on Tuesday. The stock opened at $3.1 per share and closed at the same price, down 3.1% from its previous closing price of $3.2. This decrease in stock value was affected by the company’s overall performance during Q2, which was lower than expected. The company attributed this increase to their cost-cutting initiatives and efficient operations management.
Despite the overall negative earnings results, MAINZ BIOMED NV remains confident in their ability to achieve their yearly goals and continue to drive growth in the coming quarters. They have already implemented several strategies which they believe will help them reach their objectives and reduce their losses in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for MYNZ. More…
| Total Revenues | Net Income | Net Margin |
| 0.79 | -28.6 | -3615.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for MYNZ. More…
| Operations | Investing | Financing |
| -19.09 | -1.93 | 6.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for MYNZ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 19.31 | 14.13 | 0.34 |
Key Ratios Snapshot
Some of the financial key ratios for MYNZ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.5% | – | -3539.7% |
| FCF Margin | ROE | ROA |
| -2663.9% | -235.0% | -90.4% |
Analysis – MYNZ Intrinsic Stock Value
At GoodWhale, we have performed an analysis of MAINZ BIOMED NV’s financials. We believe that the fair value of their share is around $12.2, calculated by our proprietary Valuation Line. This figure is nearly four times higher than their current stock price which is trading at $3.1, making the share 74.7% undervalued. More…
Peers
These firms are continuously innovating to provide consumers with the best possible products, services, and prices. Mainz Biomed NV has positioned itself as a leader in the industry, consistently striving to stay ahead of its competitors in terms of quality, customer service, and technological advancements.
– IDenta Corp ($OTCPK:IDTA)
IDenta Corp is a technology company dedicated to providing innovative products and services for the forensic and security markets. The company’s market cap of 3.03M as of 2023 reflects its relatively small size, yet it has a high Return on Equity of 26.84%. This suggests that the company is efficiently allocating its resources and is producing a high return on its investments. IDenta Corp focuses on developing new technologies that can be used in areas such as homeland security, counter-terrorism, narcotics, explosives, and chemical detection. The company provides a variety of products and services to the global marketplace, including training, rapid deployment kits, and educational programs.
– Genetics Generation Advancement Corp ($TPEX:4160)
Genetics Generation Advancement Corp is a biotechnology company that specializes in genetic research and development. It has a market cap of 826.82M as of 2023 and a Return on Equity of 6.13%. This indicates that the company is performing well financially, as the return on equity is relatively high compared to other companies in the industry. The company has a strong presence in the genetic research and development world, and has seen consistent growth over the past few years.
– Shanghai Labway Clinical Laboratory Co Ltd ($SZSE:301060)
Shanghai Labway Clinical Laboratory Co Ltd is a Chinese medical technology company that specializes in the development, production and sale of clinical diagnostic tests for the diagnosis and management of common diseases. As of 2023, the company has a market cap of 8.24 billion and a return on equity of 29.66%. This market cap reflects the strong performance of the company and its ability to generate returns for investors. The high ROE indicates Shanghai Labway’s ability to generate profits from its investments, while the relatively low market cap offers investors the potential for long-term growth.
Summary
MAINZ BIOMED NV reported their second quarter FY2023 earnings, with total revenue at USD 0.2 million and net income of USD -8.2 million. This was a 78.6% increase in revenue from the same quarter last year, and an improvement in the net income results. The stock price reacted negatively to the earnings announcement, indicating that investors are not satisfied with the company’s performance. Analysts will continue to monitor MAINZ BIOMED NV’s financials in order to determine whether the current trend is sustainable or if it suggests underlying weaknesses in the company’s financial position.
Related Posts
Recent Posts
